Actively Recruiting

Phase 4
Age: 19Years +
All Genders
NCT06696235

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

Led by Samsung Medical Center · Updated on 2026-01-05

408

Participants Needed

2

Research Sites

234 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO \[The Kidney Disease: Improving Global Outcomes\] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.

CONDITIONS

Official Title

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

Who Can Participate

Age: 19Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • At least 19 years old
  • Diagnosed with cardiogenic shock classified as SCAI Shock C, D, or E requiring VA-ECMO
  • Classic cardiogenic shock (Stage C) defined by: systolic blood pressure <90 mmHg for >30 min or needing catecholamines to maintain >90 mmHg; signs of pulmonary congestion; and signs of impaired organ perfusion such as altered mental status, cold skin, low urine output (<30 ml/h), or serum lactate >2.0 mmol/l
  • SCAI Shock D: failure to respond to initial interventions with worsening condition
  • SCAI Shock E: cardiac arrest needing ongoing CPR and VA-ECMO
  • Developed acute kidney injury stage 2 or higher within 48 hours of cardiogenic shock onset, defined by either a 2-fold or greater increase in serum creatinine or urine output ≤0.5 ml/kg/h for ≥12 hours
Not Eligible

You will not qualify if you...

  • Shock caused by hypovolemia, sepsis, or obstruction
  • Immediate criteria requiring CRRT before enrollment, including serum potassium >6.5 mmol/L or >6.0 mmol/L despite treatment, severe metabolic acidosis (pH <7.15 with low PaCO2 or bicarbonate <12 mmol/L), blood urea nitrogen ≥100 mg/dL, or diuretic-resistant volume overload or pulmonary edema
  • Unwitnessed out-of-hospital cardiac arrest with low Glasgow coma scale (<8) after return of circulation
  • Chronic kidney disease with eGFR <30 mL/min/1.73m2 or end-stage kidney disease on dialysis
  • Kidney transplant within the past year
  • Received any renal replacement therapy in the last 2 months
  • Known intolerance to heparin
  • Severe other diseases limiting life expectancy to less than 6 months
  • Pregnancy or breastfeeding
  • Do not resuscitate order
  • Drug overdose or toxins requiring dialysis
  • Suspected post-renal acute kidney injury due to obstruction or certain kidney diseases
  • Physician decision to start or defer renal replacement therapy immediately

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Samsung Medical Center

Seoul, South Korea, 06351

Actively Recruiting

2

Samsung Medical Center

Seoul, South Korea

Not Yet Recruiting

Loading map...

Research Team

J

Jeong Hoon Yang, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here